Document Detail

Solifenacin at 3 years: a review of efficacy and safety.
MedLine Citation:
PMID:  18654073     Owner:  NLM     Status:  MEDLINE    
Now on the market in the United States for almost 3 years and available in 48 countries worldwide, solifenacin 5 mg or 10 mg once daily continues to demonstrate a profile of safety and efficacy as a treatment for incontinence, urgency, and other symptoms of OAB. More than 2.2 million patients have been treated worldwide with solifenacin. Safety and efficacy data across numerous studies in several thousand patients, along with flexible dosing, support the use of this agent as a first-line antimuscarinic treatment for OAB. Data from large randomized controlled trials such as VENUS and STAR show statistically significant superiority compared with placebo and improved outcomes over those achieved with tolterodine ER 4 mg. Solifenacin is an agent of choice for OAB-related incontinence, with more than 50% of incontinent patients reporting no incontinence episodes after 12 weeks of solifenacin therapy. In addition to improved efficacy, solifenacin offers good tolerability with a low incidence of side effects. Once-daily, flexible dosing with this agent provides 24-hour control of OAB symptoms and significantly increases warning time (the period from onset of urgency to voiding), which may also increase a patient's chance of avoiding episodes of incontinence.
Richard S Pelman; James P Capo; Sergio Forero-Schwanhaeuser
Related Documents :
8552743 - Improved hypertension control after disclosure of decades-old trauma.
24572563 - Reviews examining sugar-sweetened beverages and body weight: correlates of their qualit...
23929643 - Dentine sensitivity: past, present and future.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Postgraduate medicine     Volume:  120     ISSN:  1941-9260     ISO Abbreviation:  Postgrad Med     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-25     Completed Date:  2008-10-21     Revised Date:  2009-02-12    
Medline Journal Info:
Nlm Unique ID:  0401147     Medline TA:  Postgrad Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  85-91     Citation Subset:  AIM; IM    
Bellevue Urology Associates, Bellevue, WA 98004, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Drug Administration Schedule
Middle Aged
Muscarinic Antagonists / pharmacokinetics,  therapeutic use*
Quinuclidines / pharmacokinetics,  therapeutic use*
Tetrahydroisoquinolines / pharmacokinetics,  therapeutic use*
Treatment Outcome
Urinary Bladder, Overactive / drug therapy*,  etiology,  physiopathology
Reg. No./Substance:
0/Muscarinic Antagonists; 0/Quinuclidines; 0/Tetrahydroisoquinolines; 0/quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
Comment In:
Postgrad Med. 2008 Nov;120(4):107-8   [PMID:  19020373 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human papillomavirus, cervical cancer, and the vaccines.
Next Document:  Dispelling the myths about omega-3 fatty acids.